Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Abstract

Our data demonstrate that natalizumab treatment reduces the accumulation of nerve injury in relapsing forms of MS. It is anticipated that highly effective anti-inflammatory treatment can reduce axonal loss, thereby preventing development of permanent neurological disability.